Perspective Therapeutics FY 2025 net loss widens 30.1% to USD 103.12 million as R&D expenses more than doubled to USD 84.22 million

Reuters03-17
<a href="https://laohu8.com/S/CATX">Perspective Therapeutics</a> FY 2025 net loss widens 30.1% to USD 103.12 million as R&D expenses more than doubled to USD 84.22 million

Perspective Therapeutics published a press release with full-year 2025 results and a business update. For FY 2025, grant revenue fell 39.2% to USD 0.88 million. FY 2025 R&D expense more than doubled to USD 84.22 million, driven by higher clinical site activities, program and delivery costs, and personnel costs, and included a USD 10 million non-cash impairment loss tied to deprioritizing an early-stage preclinical asset. FY 2025 net loss widened 30.1% to USD 103.12 million, or USD 1.4 per share, and cash, cash equivalents and short-term investments were USD 145 million at year-end. Chief Executive Thijs Spoor said the company expects multiple clinical data readouts in 2026, and said cash plus net proceeds of about USD 164 million from a subsequent equity offering are expected to fund planned milestones and operational investments into late 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603161607PRIMZONEFULLFEED9672947) on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment